Srinagar, June 11: In a moment of pride for Indian and Kashmiri Dermatology, a breakthrough clinical study authored by Dr Mir Shahnawaz, a renowned Dermatologist and Founder & Director of DERMIS Skin & Hair Clinic, Bemina, has been recognized and published in the internationally acclaimed CUREUS Journal, indexed on PubMed and hosted by Springer.
The study, titled “Clinical Assessment of Abrocitinib, Tofacitinib, and Cyclosporine in Adult Patients With Moderate to Severe Atopic Dermatitis: A Retrospective Analysis”, is the first comparative real-world research from India to evaluate the clinical efficacy and safety of these systemic therapies—most notably Abrocitinib, a selective JAK-1 inhibitor representing a new class of targeted immunomodulatory drugs.
Dr Shahnawaz is among the very few Dermatologists in India to have personally used and strongly advocated Abrocitinib as an effective and well-tolerated treatment option for patients with moderate to severe Atopic Dermatitis.
The international publication of this study not only brings recognition to the growing academic contributions of Kashmiri clinicians but also fills a critical gap in Indian dermatology literature by providing region-specific data on emerging therapies.
